How to design potent and selective DYRK1B inhibitors? Molecular modeling study

Area of Science:

• Biochemistry
• Structural Biology
• Medicinal Chemistry

Background:

• Dual-specificity tyrosine-ான்-related kinase 1B (DYRK1B) is overexpressed in cancers and promotes chemoresistance by maintaining cancer cell quiescence.
• Developing potent and selective DYRK1B inhibitors is crucial for anticancer therapy.
• Glycogen synthase kinase 3 beta (GSK3β) is a known off-target, sharing substrate phosphorylation sites and impacting cell cycle regulation.

Purpose of the Study:

• To perform a comparative structural analysis of DYRK1B and GSK3β ATP-binding sites.
• To identify key residues and regions responsible for selectivity between DYRK1B and GSK3β.
• To guide the design of potent and selective DYRK1B inhibitors.

Main Methods:

• Comparative modeling and metadynamics simulations to generate a DYRK1B homology model.
• Docking studies and calculation of interaction energies within the ATP-binding sites.
• Detailed analysis of gatekeeper and other key residues for kinase selectivity.

Main Results:

• Identified specific structural differences in the ATP-binding sites of DYRK1B and GSK3β.
• Pinpointed key residues, including the gatekeeper residues, that dictate selectivity.
• Discovered two additional residues crucial for selective DYRK1B inhibition over GSK3β.

Conclusions:

• Structural insights enable the rational design of selective DYRK1B inhibitors.
• This analysis supports the development of azaindole-quinoline-based DYRK1B inhibitors.
• Facilitates the creation of more selective inhibitors targeting DYRK kinases for cancer therapy.